Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea

Tuberculosis and Respiratory Diseases

article

Ho-Kee Yum¹  Hak-Ryul Kim²  Yoon Soo Chang³  Kyeong-Cheol Shin⁴  Song Kim⁵  Yeon-Mok Oh⁶ 

[1] Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine;Department of Internal Medicine, Wonkwang University School of Medicine;Department of Internal Medicine, Yonsei University College of Medicine;Division of Pulmonology and Allergy, Department of Internal Medicine, Regional Center for Respiratory Disease, Yeungnam University College of Medicine;Novartis Korea Ltd.;Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine

关键词: Indacaterol;    Pulmonary Disease;    Chronic Obstructive;    Safety;    Bronchodilator Agents;    Therapeutics;    South Korea;   

DOI  :  10.4046/trd.2017.80.1.52

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

Background Inhaled indacaterol (Onbrez Breezhaler), a long-acting β 2 -agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-marketing surveillance study conducted to evaluate the real-world safety and effectiveness of indacaterol in the Korean population. Methods This was an open-label, observational, prospective study in which COPD patients, who were newly prescribed with indacaterol (150 or 300 µg), were evaluated for 12 or 24 weeks. Safety was assessed based on the incidence rates of adverse events (AEs) and serious adverse events (SAEs). Effectiveness was evaluated based on physician's assessment by considering changes in symptoms and lung function, if the values of forced expiratory volume in 1 second were available. Results Safety data were analyzed in 1,016 patients of the 1,043 enrolled COPD patients receiving indacaterol, and 784 patients were included for the effectiveness analysis. AEs were reported in 228 (22.44%) patients, while 98 (9.65%) patients reported SAEs. The COPD condition improved in 348 patients (44.4%), while the condition was maintained in 396 patients (50.5%), and only 40 patients (5.1%) exhibited worsening of ailment as compared with baseline. During the treatment period, 90 patients were hospitalized while nine patients died. All deaths were assessed to be not related to the study drug by the investigator. Conclusion In real-life clinical practice in South Korea, indacaterol was well tolerated in COPD patients, and can be regarded as an effective option for their maintenance treatment.

【 授权许可】

CC BY-NC